Literature DB >> 23407478

Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples.

Serena Fortuna1, Enzo Ragazzoni, Lucia Lisi, Simona Di Giambenedetto, Massimiliano Fabbiani, Pierluigi Navarra.   

Abstract

BACKGROUND: An ultra-performance liquid chromatography-tandem mass spectrometry method was developed for the quantification of raltegravir (RTG) plasma concentrations in samples from HIV patients treated with the drug.
METHODS: Plasma samples were extracted by liquid-liquid extraction followed by evaporation to dryness and reconstitution in mobile phase. The chromatographic separation was carried out on an AQUITY UPLC C18 column with an isocratic mobile phase consisting of water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid (50:50 vol/vol). The detection was performed on a triple quadrupole tandem mass spectrometer using multi-reaction monitoring via electrospray ionization source with positive ionization mode.
RESULTS: Under these conditions, a single chromatographic run could be completed within 1 minute. The method was validated by estimating the precision and the accuracy for inter- and intra-day analysis in the concentration range of 5-2560 ng/mL. The method was linear over the investigated range with all the correlation coefficients, r, greater than 0.995 on 5 replicates. The intra- and inter-day precision (percentage of coefficient of variation) ranged from 2.4% to 11.2%, and the inaccuracy (percent of relative standard deviation) ranged from 2.5% to 12.9%. No significant matrix effect was observed. The mean recovery value of RTG was 80%.
CONCLUSIONS: This rapid and sensitive method was validated and could be applied to pharmacokinetic studies for the determination of RTG concentrations in human plasma samples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407478     DOI: 10.1097/FTD.0b013e318280110d

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.

Authors:  Ajay Gupta; Swati Guttikar; Priyanka A Shah; Gajendra Solanki; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2014-10-23

2.  Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.

Authors:  Leïla Belkhir; Carole Seguin-Devaux; Laure Elens; Caroline Pauly; Nicolas Gengler; Serge Schneider; Jean Ruelle; Vincent Haufroid; Bernard Vandercam
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

3.  Study on the pharmacokinetics, tissue distribution and excretion of laurolitsine from Litsea glutinosa in Sprague-Dawley rats.

Authors:  Yin-Feng Tan; Rui-Qi Wang; Wen-Ting Wang; Ying Wu; Ning Ma; Wei-Ying Lu; Yong Zhang; Xiao-Po Zhang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.